Osteoclastogenesis Responds to STING Inhibition in a Non-Monotonic Manner

Area of Science:

• Immunology
• Bone Biology
• Pharmacology

Background:

• Stimulator of interferon genes (STING) has paradoxical roles in bone metabolism, complicating its use for osteoporosis treatment.
• Osteoporosis is a significant health concern characterized by bone loss and increased fracture risk.

Purpose of the Study:

• To elucidate the temporal role of STING in osteoclast differentiation and bone homeostasis.
• To investigate the therapeutic window for STING inhibition in osteoporosis using a STING inhibitor (C-176).

Main Methods:

• Utilized ovariectomy (OVX)-induced osteoporosis mouse models.
• Generated osteoblast-specific Sting knockout mice.
• Employed in vitro osteoclastogenesis models.
• Administered STING inhibitor C-176 at different time points.
• Analyzed STING downstream nuclear factor kappa-B (NF-κB) and interferon (IFN) pathways.

Main Results:

• STING temporally regulates osteoclast differentiation but does not affect osteoblast-mediated bone homeostasis.
• Timed administration of C-176 showed a non-monotonic bone response; early intervention increased bone mass, while late intervention exacerbated bone loss.
• Osteoblast-specific Sting knockout mice exhibited normal bone mass.
• In vitro assays demonstrated that STING's temporal partitioning of NF-κB and IFN pathways bidirectionally controls osteoclast differentiation.

Conclusions:

• STING plays a critical temporal role in osteoclastogenesis, distinct from its role in osteoblast function.
• An early therapeutic window exists for STING inhibition to increase bone mass in osteoporosis.
• A timed therapeutic strategy is crucial for maximizing osteoprotective effects and avoiding adverse outcomes in osteoporosis treatment.